May 11, 2025
Who Stops GA Therapy—and Why
An analysis of patients receiving complement inhibitors finds baseline wet AMD and poor vision linked to treatment discontinuation.
2025 Retina World Congress
Related Articles
May 11, 2025
A Shift in Strategy for Ocular Melanoma
Timothy Murray, MD, shares 5-year data from a large series of small choroidal melanomas that indicates early treatment improves survival and preserves vision.
May 11, 2025
A Suprachoroidal Route to Retinal Therapy
Suprachoroidal gene delivery emerges as a promising alternative to subretinal or intravitreal injections.
May 11, 2025
Migaldendranib May Move the Needle in AMD, DME
Michael A. Singer, MD, shares early phase 2 data supporting D-4517.2 as a safe and effective subcutaneous therapy that reduces injection burden and preserves vision.
May 11, 2025
New Hope for Stargardt Patients
Six companies are actively developing therapies for Stargardt disease that aim to slow vision loss through various mechanisms.
May 10, 2025
Reducing the Risk of Radiation Retinopathy
New strategies aim to preserve vision after uveal melanoma treatment.
May 10, 2025
AI Tools Can Help Low-Vision Patients
Mitul Mehta, MD, discusses how voice-guided apps and wearable devices help patients read, recognize faces, and navigate.
May 10, 2025
Real-World nAMD Treatment Patterns Reveal Cost of Switching
Analysis of Medicare claims show increases in drug-related expenditures after initial low-cost therapy.
May 10, 2025
EYP-1901 Shows Durable, Sustained Efficacy in VERONA
Carl Regillo, MD, presented new data from the VERONA phase 2 clinical trial of EYP-1901 for DME at Retina World Congress.
May 10, 2025
Efficacy Data on Eye Drop for DME Presented at RWC
Statistically significant retinal thickness reductions and BVCA gains were maintained to 12 weeks.
May 9, 2025
FDA Shares Insights on Treatment Approvals, Clinical Trial Design
Dr. William Boyd, head of the FDA’s ophthalmology division, discussed his agency and answered questions related to retinal trials at RWC 2025.
May 9, 2025
Pooled Data on NT-501 Presented at RWC
Neurotech's Encelto is the first FDA-approved therapy for patients with macular telangiectasia.
May 9, 2025
Fas Inhibition Shows Neuroprotective Benefit for GA
In a phase 1b study, eyes treated with ONL1204 demonstrated reductions in geographic atrophy lesion growth.
May 9, 2025
PRISM Trial Update Presented at RWC
4D-150 is designed for single, low-dose intravitreal delivery for transgene expression from the retina.
May 9, 2025
Current Pipeline for Noninfectious Uveitis
Systemic and local treatments being investigated in clinical trials include TYK2/JAK1 modulators and IL-6 inhibitors.